03:24 AM EDT, 08/12/2024 (MT Newswires) -- Dana Aftab, Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, on August 07, 2024, sold 95,000 shares in Exelixis ( EXEL ) for $2,375,000. Following the Form 4 filing with the SEC, Aftab has control over a total of 526,825 shares of the company, with 520,990 shares held directly and 5,835 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/939767/000093976724000126/xslF345X03/wk-form4_1723246333.xml

Price: 27.00, Change: +0.03, Percent Change: +0.11